{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:11:31Z","timestamp":1788293491280,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cRicerca Corrente\u201d funding scheme of the Ministry of Health, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: The use of fractional exhaled nitric oxide (FeNO) has been proposed for identifying and monitoring eosinophilic airway inflammation in chronic obstructive pulmonary disease (COPD). To explore the clinical utility of FeNO in COPD, we aimed to assess its short-term variability in a clinically stable COPD cohort. Methods: Consecutive COPD patients, formerly smokers, underwent FeNO assessment at the baseline and six time-points through serial sampling spaced 3 days apart. Results: A total of 41 patients (mean age 72.9, 87.8% males) showed a median baseline value of FeNO of 11.7 (8.0\u201316.8) ppb. A weak linear relationship was documented between baseline FeNO values and both eosinophil counts (r = 0.341, p = 0.029) and the percentage of eosinophils (r = 0.331, p = 0.034), confirmed in multiple linear regressions after adjusting for steroid use. The overall individual variability of FeNO between time-points was 3.90 (2.53\u20137.29) ppb, with no significant difference in the distribution of FeNO values measured at different time-points (p = 0.204). A total of 28 (68.3%) patients exhibited FeNO always below the 25 ppb cut-off at all determinations, while the remining 13 (31.7%) had at least one value above the established limit. Interestingly, none of these 13 participants had FeNO stably above 25 ppb, all showing at least one normal value during serial sampling. Compared to these patients with more fluctuating values, the 28 with stably normal FeNO only exhibited a significantly higher body weight (80.0 \u00b1 18.2 kg vs. 69.0 \u00b1 8.8 kg, p = 0.013) and body mass index (29.7 \u00b1 6.5 kg\/m2 vs. 25.9 \u00b1 3.7 kg\/m2, p = 0.026), confirmed in multiple logistic regressions after adjusting for major potential confounders. Conclusions: A certain degree of FeNO variability, apparently unrelated to eosinophil counts but somehow influenced by body weight, must be considered in COPD patients. Further studies are needed to clarify whether this biomarker may be effectively used to plan more personalized pharmacological and rehabilitation strategies in this clinical setting.<\/jats:p>","DOI":"10.3390\/jpm12111906","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T02:31:27Z","timestamp":1668565887000},"page":"1906","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Fractional Exhaled Nitric Oxide (FeNO) in Patients with Stable Chronic Obstructive Pulmonary Disease: Short-Term Variability and Potential Clinical Implications"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-0428","authenticated-orcid":false,"given":"Pasquale","family":"Ambrosino","sequence":"first","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Cardiac Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Fuschillo","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasofia","family":"Accardo","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mosella","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-9640","authenticated-orcid":false,"given":"Antonio","family":"Molino","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Alfredo","family":"Spedicato","sequence":"additional","affiliation":[{"name":"Department of Statistics and Quantitative Methods, Milano-Bicocca University, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-658X","authenticated-orcid":false,"given":"Andrea","family":"Motta","sequence":"additional","affiliation":[{"name":"Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-9921","authenticated-orcid":false,"given":"Mauro","family":"Maniscalco","sequence":"additional","affiliation":[{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037 Telese Terme, Italy"},{"name":"Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease GOLD Executive Summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1183\/09031936.00171614","article-title":"COPD comorbidities network","volume":"46","author":"Divo","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e010510","DOI":"10.1161\/JAHA.118.010510","article-title":"Management and 1-Year Outcomes of Patients with Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry","volume":"8","author":"Goto","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.clnu.2019.11.016","article-title":"Coexistence of malnutrition, frailty, physical frailty and disability in patients with COPD starting a pulmonary rehabilitation program","volume":"39","author":"Wempe","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1378\/chest.13-1703","article-title":"Disability in Patients With COPD","volume":"145","author":"Yohannes","year":"2014","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11739-017-1690-0","article-title":"Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: A systematic review with meta-analysis","volume":"12","author":"Ambrosino","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2147\/COPD.S92133","article-title":"Health care and social care costs of pneumonia in Denmark: A register-based study of all citizens and patients with COPD in three municipalities","volume":"10","author":"Poulsen","year":"2015","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.rmed.2007.08.001","article-title":"Costs of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes)","volume":"102","author":"Negro","year":"2008","journal-title":"Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2147\/COPD.S167357","article-title":"Social economic costs of COPD in Extremadura (Spain): An observational study","volume":"13","author":"Merino","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4187\/respcare.09627","article-title":"Community-Based Pulmonary Rehabilitation Programs in Individuals With COPD","volume":"67","author":"Barbosa","year":"2022","journal-title":"Respir. Care"},{"key":"ref_12","first-page":"100932","article-title":"Effects of pulmonary rehabilitation on fear of falling in Chronic Obstructive Pulmonary Disease (COPD) patients: An observational study","volume":"82","author":"Berriet","year":"2022","journal-title":"Respir. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zampogna, E., Ferriero, G., Visca, D., Patrini, M., Negrini, S., and Arienti, C. (Panminerva Med., 2022). An Overview of Cochrane Systematic Reviews for pulmonary rehabilitation interventions in people with COPD: A mapping synthesis, Panminerva Med., Online ahead of print.","DOI":"10.23736\/S0031-0808.22.04757-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2796.2007.01837.x","article-title":"Aspects on pathophysiological mechanisms in COPD","volume":"262","author":"Larsson","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","article-title":"Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations","volume":"41","author":"Ritchie","year":"2020","journal-title":"Clin. Chest Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191209","DOI":"10.5696\/2156-9614-9.24.191209","article-title":"Eosinophilic Airway Inflammation in Patients with Stable Biomass Smoke- versus Tobacco Smoke-Associated Chronic Obstructive Pulmonary Disease","volume":"9","author":"Fernandes","year":"2019","journal-title":"J. Health Pollut."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Oishi, K., Matsunaga, K., Shirai, T., Hirai, K., and Gon, Y. (2020). Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082670"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/thx.2005.056093","article-title":"Exhaled nitric oxide measurements: Clinical application and interpretation","volume":"61","author":"Taylor","year":"2006","journal-title":"Thorax"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"036006","DOI":"10.1088\/1752-7163\/aa746b","article-title":"Differential effect of cigarette smoke exposure on exhaled nitric oxide and blood eosinophils in healthy and asthmatic individuals","volume":"11","author":"Jacinto","year":"2017","journal-title":"J. Breath Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1164\/rccm.200510-1659PP","article-title":"Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease","volume":"174","author":"Barnes","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1183\/20734735.0268-2019","article-title":"Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD","volume":"15","author":"Turner","year":"2019","journal-title":"Breathe"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1164\/ajrccm.157.3.97-05009","article-title":"Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease","volume":"157","author":"Maziak","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/15412555.2018.1482532","article-title":"Value of Exhaled Nitric Oxide (FeNO) And Eosinophilia During the Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospital Admission","volume":"15","author":"Moragues","year":"2018","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2147\/COPD.S165780","article-title":"Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis","volume":"13","author":"Lu","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1475-097X.2010.00975.x","article-title":"Repeatability of exhaled nitric oxide measurements in patients with COPD","volume":"31","author":"Rouhos","year":"2010","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.pupt.2008.04.006","article-title":"Exhaled nitric oxide monitoring in COPD using a portable analyzer","volume":"21","author":"Maniscalco","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/00039890209601434","article-title":"Transient Decrease of Exhaled Nitric Oxide after Acute Exposure to Passive Smoke in Healthy Subjects","volume":"57","author":"Maniscalco","year":"2002","journal-title":"Arch. Environ. Health Int. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2362.2011.02501.x","article-title":"Measurement of nasal nitric oxide by hand-held and stationary devices","volume":"41","author":"Montella","year":"2011","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","article-title":"Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society","volume":"155","author":"Qaseem","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur. Respir. J. Suppl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1183\/09031936.05.00035005","article-title":"Standardisation of the measurement of lung volumes","volume":"26","author":"Wanger","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1183\/09031936.00142010","article-title":"Reproducibility of 6-minute walking test in patients with COPD","volume":"38","author":"Hernandes","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"021002","DOI":"10.1088\/1752-7163\/ab0167","article-title":"Comparison of three different exhaled nitric oxide analyzers in chronic respiratory disorders","volume":"13","author":"Molino","year":"2019","journal-title":"J. Breath Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2022, September 06). Global Strategy for the Diagnosis, m., and Prevention of CHRONIC obstructive Pulmonary Disease 2020 Report. Available online: http:\/\/www.goldcopd.org."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/thoraxjnl-2014-206069","article-title":"Asthma biomarkers: What constitutes a \u2018gold standard\u2019?","volume":"70","author":"Arron","year":"2014","journal-title":"Thorax"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-018-0248-7","article-title":"Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma","volume":"14","author":"Gao","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4081\/mrm.2020.36","article-title":"Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: A position paper of the Italian Respiratory Society (SIP\/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.chest.2016.10.003","article-title":"Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions","volume":"151","author":"Couillard","year":"2017","journal-title":"Chest"},{"key":"ref_43","first-page":"e4985","article-title":"Global Initiative for Chronic Obstructive Lung Disease: The Changes Made","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"ref_44","unstructured":"(2022, June 24). Global Initiative on Asthma. Available online: www.ginasthma.org."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"00437","DOI":"10.1183\/23120541.00437-2020","article-title":"Targeted therapy in eosinophilic chronic obstructive pulmonary disease","volume":"7","author":"Fieldes","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mjosberg","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_50","first-page":"3109","article-title":"Type 2 innate lymphoid cells participate in IL-33-stimulated Th2-associated immune response in chronic obstructive pulmonary disease","volume":"18","author":"Jiang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1513\/AnnalsATS.201403-097AW","article-title":"Type-2 Innate Lymphoid Cells in Asthma and Allergy","volume":"11","author":"McKenzie","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/ni0816-1005c","article-title":"Erratum: Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs","volume":"17","author":"Silver","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11882-015-0581-6","article-title":"Insights into Group 2 Innate Lymphoid Cells in Human Airway Disease","volume":"16","author":"Karta","year":"2016","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_54","first-page":"CD013432","article-title":"Anti-IL-5 therapies for chronic obstructive pulmonary disease","volume":"12","author":"Donovan","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1602486","DOI":"10.1183\/13993003.02486-2016","article-title":"A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis","volume":"49","author":"Dasgupta","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1056\/NEJMc1715454","article-title":"Mepolizumab for Eosinophilic COPD","volume":"378","author":"Sciurba","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: Analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thoraxjnl-2020-214644","article-title":"Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease","volume":"77","author":"Annangi","year":"2021","journal-title":"Thorax"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.arbres.2021.11.013","article-title":"Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial","volume":"58","author":"Su","year":"2022","journal-title":"Arch. De Bronconeumol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/crj.12518","article-title":"Response of exhaled nitric oxide to inhaled corticosteroids in patients with stable COPD: A systematic review and meta-analysis","volume":"12","author":"Lim","year":"2016","journal-title":"Clin. Respir. J."},{"key":"ref_65","first-page":"5753524","article-title":"Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma","volume":"2022","author":"Acevedo","year":"2022","journal-title":"BioMed Res. Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0042-1743290","article-title":"FeNO in Asthma","volume":"43","author":"Loewenthal","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/15412555.2018.1485637","article-title":"Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review","volume":"15","author":"Naderi","year":"2018","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.orcp.2015.11.006","article-title":"Association between Body Mass Index (BMI) and fraction of exhaled nitric oxide (FeNO) levels in the National Health and Nutrition Examination Survey (NHANES) 2007\u20132010","volume":"10","author":"Uppalapati","year":"2016","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.orcp.2015.03.004","article-title":"Low alveolar and bronchial nitric oxide in severe uncomplicated obesity","volume":"9","author":"Maniscalco","year":"2015","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.resp.2006.10.003","article-title":"Exhaled nitric oxide in severe obesity: Effect of weight loss","volume":"156","author":"Maniscalco","year":"2007","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lee, H., Shin, S.H., Gu, S., Zhao, D., Kang, D., Joi, Y.R., Suh, G.Y., Pastor-Barriuso, R., Guallar, E., and Cho, J. (2018). Racial differences in comorbidity profile among patients with chronic obstructive pulmonary disease. BMC Med., 16.","DOI":"10.1186\/s12916-018-1159-7"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/11\/1906\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:19:03Z","timestamp":1760145543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/11\/1906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jpm12111906"],"URL":"https:\/\/doi.org\/10.3390\/jpm12111906","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}